As always, there are exciting things happening behind the scenes at Neuromics. This week, we added three cell lines of human fibroblasts. In addition to the new cells, we also received a publication with researchers using human cells from Neuromics.
Like I said, we are now offering three human fibroblast cell lines. They are HEL 299 cells (cat.no. HEL001), MRC-5 cells (cat.no. MRC001), and WI-38 cells (cat.no. WI001). All three are immortalized cell lines derived from fetal lung tissue in the 1960s. These cell lines are known for their use in vaccine research and production, but have many other applications.
Image: Neuromics human brain microvascular pericytes stained with VWF/Factor VIII (dilution 1:100). Secondary antibody conjugated to Alexa 594 (red) and counterstained with DAPI (blue). Cells were mounted using iBrite mounting media.
Moving on to the new publication, last month, researchers from the University of Copenhagen published research on glioblastoma surgery using our human brain astrocytes (cat.no. HMP202) and human brain microvascular pericytes (cat.no. HMP104).
Read more to learn more about the publication...
Glioblastoma can really only be effectively treated through surgical procedures to remove the tumor, with no other curative treatments available. However, removing as much of the tumor as possible while preserving healthy brain tissue is complicated by the irregular shape of glioblastoma tumors.
These scientists and doctors built a probe targeting urokinase-type Plasminogen Activator Receptor (uPAR), a protein expressed in glioblastoma tumors, for use in fluorescence guided surgery. In mice xenografts, they had success visualizing glioblastoma tumors after injection of the probe. Using our astrocytes and pericytes, the researchers constructed a 3D BBB model that demonstrated the probe could pass the BBB.
Check out the products mentioned in the blog post below:
| Name | Catalog # | Type | Species | Applications | Size | Price |
|---|---|---|---|---|---|---|
| Astrocyte-Growth Media | PGB003 | Cell Growth Media | Human | Cell Assays | 500 ml | $272.40 |
| HEL 299 Cells | HEL001 | Primary Cells | Human | Cell Assays | 500,000 Cells | $905.76 |
| Human Brain Astrocytes (HBA) | HMP202 | Primary Cells | Human | Cell Assays | 500,000+ cells - Frozen | $965.94 |
| Human Brain Microvascular Pericytes (HBMVPCs) | HMP104 | Primary Cells | Human | Cell Assays | 500,000+ Cells - Frozen | $965.94 |
| MRC-5 Cells | MRC001 | Primary Cells | Human | Cell Assays | 500,000 Cells | $905.76 |
| Pericyte-Growth Media | PGB001 | Cell Growth Media | Human | Cell Assays | 500 ml | $272.40 |
| WI-38 Cells | WI001 | Primary Cells | Human | Cell Assays | 500,000 Cells | $905.76 |
Citation:
Sorel Kurbegovic, Karina Juhl, Kasper Kildegaard Sorensen, Julie Leth, Gro Linno Willemoe, Anders Christensen, Yvonne Adams, Anja Ramstedt Jensen, Christian Von Buchwald, Jane Skjoth-Rasmussen, Michael Ploug, Knud J. Jensen, Andreas Kjaer. (2021). IRDye800CW Labeled uPAR-Targeting Peptide for Fluorescence-Guided Glioblastoma Surgery: Preclinical Studies in Orthotopic Xenografts.Theranostics, 11(15): 7159-7174. doi: 10.7150/thno.49787